To study the potential involvement of growth hormone-releasing hormone (GHRH) in the generation of growth hormone (GH) pulses in humans we have used a competitive antagonist to the GHRH receptor, (N-Ac-Tyr',D-Arg2)GHRH(l-29)NH2(GHRH-Ant). Six healthy young men were given a bolus injection of GHRH-Ant 400 ,g/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h. Integrated total and pulsatile GH secretion were suppressed during GHRH-Ant treatment by 40±6 (SE) % and 75±5%, respectively. GHRHAnt suppressed maximum (7.6±2.2 vs 1.8±0.5 ,ug/liter; P < 0.001) and mean (3.3±1.0 vs 1.1±0.2 ,gg/liter; P = 0.02) GH pulse amplitudes. There was no change in integrated nonpulsatile GH levels, pulse frequency, or interpulse GH concentration. GHRH-Ant 400 ,g/kg also suppressed the GH responses to intravenous boluses of GHRH 0.33 ag/kg given 1, 6, 12, and 24 h later by 95, 81, 59, and 4%, respectively. In five healthy men, the responses to 10-fold larger GHRH boluses (3.3 tg/kg) were suppressed by 82 and 0%, 1 and 6 h after GHRH-Ant 400 ggg/kg, respectively. These studies provide the first direct evidence that endogenous GHRH participates in the generation of spontaneous GH pulses in humans. (J. Clin. Invest. 1993. 92:695-701.)
Introduction
Growth hormone (GH)' secretion is pulsatile in all species studied thus far. GH release appears to be under dual control by two hypothalamic peptides, GH-releasing hormone (GHRH) and somatostatin (SRIF) , which promote and inhibit GH secretion, respectively. The importance of GHRH pulses as generators ofpulsatile GH secretion has been directly studied in vivo in several animal species. In the rat, both immunoneutralization of GHRH (1, 2) and abolition of GHRH secretion (3, 4) eliminate GH pulses, whereas administration of SRIF antibody increases interpulse GH concentrations ( 1, 5) . Direct sampling of rat (1) or sheep (6) hypophysial-portal blood has found GHRH peaks to be largely concurrent with GH pulses, validating the analysis of GH pulsatility as a method for the study of endogenous GHRH secretion in these species.
Multiple human studies have assessed GH pulsatility in various physiologic conditions, such as puberty (7), aging (8) , fasting (9) , and the menstrual cycle (10) , as well as in human illnesses such as growth delay ( 1), acromegaly ( 12, 13) , diabetes ( 14) , and obesity ( 15 ). The underlying assumption in the interpretation ofthese experiments has been that in humans, as in rats and sheep, GH pulses reflect periodic discharges ofhypothalamic GHRH, whereas interpulse GH levels are set by tonic SRIF secretion. However, whether GHRH plays such a role in the generation of pulsatile GH secretion in humans is unknown. Peripheral blood concentrations of GHRH ( 16) or SRIF ( 17) do not reflect pituitary portal blood levels and the direct approaches that have been used in animal studies are not practical in humans. Since there are large species-specific differences in the neuroendocrine control of GH secretion, animal data cannot be directly extrapolated to humans. For example, acute hypoglycemia results in a decrease in GH secretion in rats ( 18) and sheep (6) , whereas the same stimulus increases GH secretion in humans (19) . Calorie deprivation increases GH secretion in sheep (20, 21 ) and humans (9) but decreases it in the rat (22) . Importantly, normal humans (23) and even GHRH-deficient children (24, 25) given continuous GHRH infusions exhibit highly pulsatile GH secretion. This implies that another stimulus, such as periodic SRIF withdrawal, may govern the generation of GH pulses and indeed, acute withdrawal of SRIF infusion does elicit acute GH response in humans (26, 27) . Establishment of the role of GHRH in the genesis of GH pulses in humans is crucial for the understanding of both normal GH secretory physiology and the neuroendocrine mechanism operative in various disease states.
(N-Ac-Tyr',D-Arg2)GHRH( 1-29)NH2(GHRH-Ant) is an analogue of GHRH that functions as a competitive antagonist at the level ofthe GHRH receptor. This was demonstrated both in rat pituitary cells (28) and in COS cells transfected with the cDNA for the human GHRH receptor (29) . It does not alter baseline GH secretion (30) but abolishes GHRH effects upon adenylate cyclase activity (28, 29) and GH release (29) (30) (31) (32) . Administration ofGHRH-Ant to rats eliminates both GH pulses and somatic growth (30) . We have used this compound to determine whether endogenous GHRH is involved in the generation of spontaneous GH pulses in humans.
Methods
Subjects and study design. The study was approved by the Food and Drug Administration, the University of Michigan Institutional Review Board, and the Clinical Research Center Review Committee. All sub-jects involved in this study signed an informed consent document. All were nonsmoking males, 20-34 yr of age, who were taking no medications and had unremarkable medical history and physical examinations. All had normal height ( 1.72-1.88 m) and body mass index (20-26 kg/M2). Screening work-ups, which included serum electrolytes, glucose, calcium, phosphorus, biochemical indices ofrenal and hepatic function, and a complete blood count, were normal in all subjects.
In every experiment, each subject was studied twice in the Clinical Research Center in an open labeled fashion, once during administration of the vehicle, normal saline, and once while receiving GHRHAnt. There was a minimum of 4 d between the completion of saline studies and the beginning of GHRH-Ant treatment days.
In experiment 1, subjects were admitted into the Clinical Research Center at 1600 h, at which time an intravenous (iv) catheter was placed in a forearm vein ofone arm for blood sampling and a second catheter was placed in a forearm vein ofthe other arm for drug administrations. Meals were served at 0700, 1300, and 1800 h and there was no between meal snacking. Water was allowed ad lib. Throughout the study, subjects were allowed to walk freely in the CRC, but refrained from vigorous activity. Lights were turned on at 0700 h and off at 2300 h. Daytime napping was not permitted.
Since most spontaneous GH secretory episodes occur at night, the effect of GHRH-Ant on spontaneous pulsatile GH secretion was assessed during the nighttime hours. In contrast, the ability of GHRHAnt to block the GH secretory effects of exogenous GHRH was tested during the waking hours as spontaneous GH pulses, which might interfere with data interpretation, would be less likely to occur. At 2200 h either 20 ml of saline or GHRH-Ant 100 ,g/kg of body weight was given intravenously over 3 min and blood pressure, heart rate, and temperature were closely monitored for the next hour. Plasma cortisol, lutenizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and prolactin were measured before and 30, 60, and 90 min after the first dose of GHRH-Ant. Blood sampling for GH was performed every 10 min from 2000 h on the day of admission until 0800 h the following morning, at which time the same dose of saline or GHRH-Ant was given. GHRH 0.33 Ag/kg iv bolus was given 1, 6, 12, and 24 h after the second dose of saline or GHRHAnt. Blood samples were obtained every 20 min, from 1 h before until 2 h after each GHRH dose. Blood was also collected for repeat measurements ofthe screening blood tests at baseline and then 1 and 24 h after the first dose of GHRH-Ant.
This experiment was done in two individuals only. As will be presented below, nocturnal pulsatile plasma GH concentrations in these subjects were only partially suppressed with GHRH-Ant 100 ag/kg. For this reason, subsequent experiments were performed using GHRH-Ant at the dose 400 ,ug/kg of body weight. In experiment 2, GHRH-Ant was administered at this higher dose to six subjects, otherwise the protocol was identical to that performed in experiment 1. In experiment 3, five subjects were admitted into the CRC at 0730 h at which time an iv catheter was placed into a forearm vein. At 0900 h they were given saline or GHRH-Ant 400 Ag/kg iv over 6-8 min.
Intravenous boluses of GHRH 3.3 gg/kg were given 1 and 6 h later (1000 and 1500 h). Blood samples were obtained every 10 min from 0830 until 0900 h and every 20 min between 0900 and 1200 h and between 1400 and 1700 h, encompassing 1 h before and 2 h after each GHRH injection. Subjects were given breakfast at 0730 h and lunch at 1200. The same limitations on between meal snacking and activity as in the previous experiments were applied.
Materials. GHRH( 1-44) was purchased from Bachem Inc. (Torrance, CA) and was prepared by the University ofMichigan Inves- tigational Pharmacy to a concentration of 50 ,g/ml. GHRH-Ant was purchased from Bachem Bioscience (Philadelphia, PA) and was prepared to a concentration of 1 or 5 mg/ml in 0.9% saline.
Assays. Plasma GH was measured in duplicate by an established radioimmunoassay (33) with materials generously donated by the National Institute of Diabetes and Digestive and Kidney Diseases Pituitary and Hormone Distribution Program. In experiments 1 and 2, all samples from each subject were run in the same assay. All samples from experiment 3 were run simultaneously. Mean intrassay coefficient of variation of replicate samples was below 8% in each assay and mean assay sensitivity was 0.27 ggg/liter. GH concentrations below assay sensitivity were assigned the value of assay sensitivity before data analysis. All other assays were performed by the Hematology, Chemistry, and Ligand Laboratories (Department of Pathology, University of Michigan Medical Center) using established methodologies.
Data analysis. Parameters of pulsatile GH concentration during the 2200 h-0800 h period were analyzed by the computer program Cluster (34) using a power fit, at statistic of 2 and a cluster size of 2 X 2 (35) . To minimize detection of false positive pulses, only computer identified pulses that were greater in amplitude (nadir to peak) than assay sensitivity were considered as true pulses. Interpulse GH was the mean GH concentration between pulses. Only segments that were both identified by Cluster as nonpulsatile GH secretion and were more than I half-life of GH (20 min) away from the end of the preceding pulse were included in the estimation of interpulse GH concentration. Integrated total GH concentration (,ug X min/ liter) was calculated as the area under the GH versus time curve (AUC) using the trapezoidal rule.
Integrated pulsatile GH concentration (gg X min/liter) was defined as the area under the GH versus time curve during time segments identified as a pulse by Cluster minus the contribution of the baseline. Baseline was calculated by the trapezoidal rule, using GH values at the beginning and the end of a pulse. Integrated nonpulsatile GH (yg x min/liter) was measured as integrated total minus the integrated pulsatile GH concentrations. Similarly, the GH responses to bolus GHRH were defined both in terms of the absolute increase from nadir to peak (,gg/liter) as well as the pulsatile area under the GH versus time curve after GHRH administration.
ANOVA for repeat measures and two-tailed paired or unpaired Student's t tests were used when appropriate for statistical comparisons between groups. If the data were not normally distributed, they were logarithimically transformed before analysis. All results are presented as mean±standard error (M±SE) and P < 0.05 was considered significant.
Results
During the baseline studies, nocturnal GH profiles were pulsatile in all eight subjects who were studied in experiments 1 and 2. Between 1 and 4 GH pulses were detected in each individual (2.8±0.4 pulses/ 10 h), with a mean pulse amplitude of 7.7±3.5 ug/liter. Administration of exogenous GHRH (0.33 dig/kg) produced a GH response of similar magnitude (6.9±1.4 ,ug/liter; P = 0.76). In the first two subjects, who received GHRH-Ant 100 ug/kg, plasma GH response to GHRH 0.33 ig/kg was suppressed by a mean of91, 62,53, and 0%, 1, 6, 12, and 24 h later (data not shown). Their nocturnal GH profiles during saline and GHRH-Ant treatment are shown in Fig. 1 . The integrated total and pulsatile GH concentrations were suppressed by an average of 47 and 53%, respectively.
In experiment 2, we used a larger dose of GHRH-Ant, 400
,gg/kg, in an attempt to more completely block both the effect of exogenous GHRH and spontaneous nocturnal GH pulsatility. The effects of GHRH-Ant 400 .g/kg on GH responses to GHRH are presented in Fig. 2 . Nearly complete (95±2%; GHRH vs saline; P = 0.0001 ) suppression was achieved when GHRH was administered 1 h after GHRH-Ant and there was a gradual disappearance of the suppressive effect of GHRH-Ant on GH responses thereafter: 81±3% at 6 h (P = 0.0001), during the overnight sampling are shown in Fig. 2 . Integrated total and pulsatile GH concentrations were suppressed by GHRH-Ant during the 10-h time period by 40±6 and 75±5%, respectively. The effects of GHRH-Ant on discrete parameters ofGH secretion in these six subjects are given in Table I . There was no change in pulse frequency, however both mean and maximum pulse amplitude were markedly decreased during GHRH-Ant treatment. There were strong correlations between the magnitude of spontaneous GH secretion during saline secretion and the residual GH secretion during GHRH-Ant for both integrated total (r = 0.88; P = 0.017) and pulsatile (r = 0.92; P = 0.001) GH concentrations. Since there was no change in the nonpulsatile component of the GH profile, the suppression of the integrated total GH concentration during GHRH-Ant treatment could be attributed entirely to its effect upon the pulsatile component of the profile.
In experiment 3, the ability of GHRH-Ant 400 jig/kg to block the effect of a 10-fold higher dose of GHRH was tested. ,ug X min/liter vs 1,439±400 ug X min/liter; GHRH-Ant vs sal; P = 0.57). GHRH-Ant was well tolerated in all subjects. After acute administration ofthe drug, there were no significant changes in blood pressure, heart rate, or body temperature. All ofthe subjects who received the dose of GHRH-Ant 400 ag/kg experienced a hot flush that began within 5 min of drug administration and lasted from 5 to 40 min. Most, but not all subjects developed erythema that was most prominent on the face, neck, torso, and arms. The erythema lasted from 10 to 40 min and was generally less intense after the second dose ofGHRHAnt. Neither ofthe two subjects who received GHRH-Ant 100 ,ug/kg had either hot flush or erythema. None of the subjects developed shortness of breath, wheezing, conjunctival or soft GHRH 0.33 pG/KG TIME OF DAY are impractical in human investigation. The introduction of a selective GHRH receptor antagonist, (N-Ac-Tyr' ,DArg2)GHRH( 1-29)NH2, provided a novel approach to study physiology of GH secretion in humans. Our data demonstrate that this compound decreases the magnitude of both GHRHinduced as well as spontaneous GH pulses in humans. This is the first direct evidence of GHRH participation in the generhation of spontaneous GH pulsatility in humans. To test the capacity of GHRH-Ant to counteract GHRH action in vivo, we assessed the inhibitory effect of this compound upon GH release induced by exogenous GHRH. We used a GHRH dose of 0.33 pg/kg since in previous studies (36-38) similar doses resulted in a half-maximal response and produced GH pulses of the same magnitude as spontaneously occurring pulses in humans (12, 38) . This dose in humans results in plasma GHRH concentrations similar to the GHRH concentrations needed for half-maximal GH stimulation in vitro (36, 39) and agrees with data on GHRH receptor binding affinity (39) . In our experiments, we found that GH responses to GHRH 0.33 ,ug/kg were similar in magnitude to the spontaneous GH pulses, suggesting that this dose, as has been concluded by others (38) , was physiological. Although there was no difference between the GH responses to GHRH 0.33 ,gg/kg and GHRH 3.3 ig/kg 1 h after saline injection, the response at 6 h was considerably greater after the larger dose of GHRH. The difference between responses at the two times during control treatment wag likely due to both high inter-and intrasubject variability ofGH responses to GHRH (36, 37) and modest group sizes. A single iv bolus of GHRH-Ant 400 ,gg/kg almost totally blocked the stimulatory effect ofGHRH 0.33 3,g/kg at 1 h and this effect gradually diminished with time. The same dose of GHRH-Ant, however, was less effective against a 10-fold larger dose of GHRH and its effect dissipated rather quickly. These data support previous in vitro and in vivo animal studies (28) (29) (30) (31) (32) (44) (45) (46) , and in vivo in both rats (47, 48) and humans (26, 27 (1, 55, 56) and GHRH antibody prevents the rebound GH secretion associated with both SRIF immunoneutralization (56) and withdrawal of a SRIF infusion (48) . Indeed, the rebound GH secretion associated with SRIF withdrawal is less prominent in vitro than in vivo (45, 57) and in humans, the rebound pulses occur less consistently and are smaller than after GHRH boluses (26, 27 The role of GHRH in determining interpulse GH concentrations is uncertain. GHRH immunoneutralization in male rats has no effect on interpulse GH concentration ( 1, 56) ; however, elimination of GHRH action (58, 59) or secretion (60) decreases interpulse GH in females. Thus, SRIF may not be the only determinant of tonic GH secretion. We have found no changes in GH interpulse levels during antagonist administration, cautiously suggesting that GHRH may not be important in the determination of interpulse GH levels in young men.
This conclusion must be tempered by the realization that many of the interpulse GH levels were at or below assay sensitivity.
Similarly, the same technical limitation has precluded us from addressing the effects of GHRH-Ant on GH "micropulses" (61 ) , that might have been hidden below our RIA detection limit. Thus, at the present time it remains uncertain whether GHRH-Ant selectively inhibits all GH pulses or reduces overall GH secretion. These questions will be better resolved with the introduction ofmore sensitive GH assays and by the assessment ofdiscrete parameters ofGH pulsatility using continuous GHRH-Ant infusions during the daytime when large GH pulses do not usually occur. Additionally, sex related differences of the effect of GHRH-Ant will have to be ascertained.
In conclusion, we have provided the first direct evidence for GHRH involvement in the regulation ofGH secretion, including the generation of spontaneous GH pulses in humans. Furthermore, our study validates the use ofGHRH antagonist as a novel paradigm to study mechanisms of GH secretion in humans. This approach will allow more precise understanding of the neuroendocrine mechanisms involved in the regulation of GH secretion in normal and pathologic states.
